Governance
Governance overview
Genome Canada was established in February 2000 under the Canada Corporations Act and, in 2012, was issued new Articles of Continuance under the Canada Not-for-Profit Corporations Act. Drawn from the academic, private and public sectors, the Genome Canada Board of Directors is made of up to 16 individuals who bring diverse experience and expertise to advance our mission to improve lives and strengthen communities through applied genomics research and innovation.
Board committees
- Science and Industry Advisory Committee (permanent committee of the Board)
- Executive Committee
- Audit and Investment Committee
- Programs Committee
- Governance, Election and Compensation Committee
- Communications and Outreach Committee
Board of Directors
Ingrid Richter
Cami Ryan
Éliane Ubalijoro
Colin Webster
Ex-Officio Advisors
The Presidents of five major federal research funding agencies (Canadian Institutes of Health Research, the Canada Foundation for Innovation, National Research Council Canada, Natural Sciences and Engineering Research Council of Canada and Social Sciences and Humanities Research Council of Canada) are Ex-Officio Advisors to the Board.
Science and Industry Advisory Committee (SIAC)
SIAC is a permanent committee of Genome Canada’s Board of Directors. The Committee is tasked with providing advice and recommendations to the board on:
- Emerging scientific research opportunities and challenges and potential areas for investment in genomics and Genomics in Society, including GE3LS research in Canada.
- International trends, developments and potential national and international collaborations.
- Areas of strategic social and economic importance to Canada.
- Application of the outcomes of genomics research including commercialization, knowledge transfer, policy development, and social and economic benefits.